Cumulative proportion of patients from whom PCR-negative harvests were obtained after either cyclophosphamide (p-CTX), cytarabine (p-AraC), or cytarabine plus ex vivo purging (ex vivo purging).

The latter group includes only patients in the high-dose sequential therapy arm.